Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE].
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PHARE
- 01 Aug 2017 Results (n=5502) assessing sequential versus concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer using patient data from NCT00381901 and SIGNAL trials published in the European Journal of Cancer
- 11 Oct 2016 Results evaluating the impact of HER expression levels in the PHARE/SIGNAL cohort (n=5474; HER2+) presented at the 41st European Society for Medical Oncology Congress
- 11 Oct 2016 Results of sequential vs concomitant incorporation of trastuzumab with chemotherapy in the PHARE/SIGNAL cohort (n=5502; HER2+) presented at the 41st European Society for Medical Oncology Congress